Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Deferoxamine and Ferric Ion

supplement:

Ferric Ion

Research Papers that Mention the Interaction

Importantly, when the DFO was preloaded together with Fe3+ [Fe(III)-DFO], the radiosensitizing effect was lost.
Radiation research  •  2001  |  View Paper
Deferoxamine is a potent chelator of ferric iron.
The inhibitory effects are reversible and are overcome when ferric iron is present along with deferoxamine in a 2:1 molar ratio.
Shock  •  1996  |  View Paper
Intracellular iron quantification indicated that, as deferoxamine , exogenous NO significantly decreased intracellular ferric iron levels in tumor cells.
Cancer research  •  2001  |  View Paper
This study demonstrates that DFO is a potent S-phase inhibitor of DNA synthesis in human lymphocytes in vitro, and this inhibitory effect of DFO is reversible by adding appropriate amounts of ferric ion.
Chinese medical journal  •  1989  |  View Paper
Addition of the iron chelator desferrioxamine to reduce the accumulation of ferric iron from heme by HO-1 resulted in blockade of the aggravated oxygen radical production.
Toxicological sciences : an official journal of the Society of Toxicology  •  2008  |  View Paper
As one potential source of ROS formation we identified the lysosomal Fe(2+) pool, since the ferric ion chelator deferoxamin inhibited ROS formation by approximately 15%.
Aquatic toxicology  •  2004  |  View Paper
The addition of Fe(III) to the dialyzed solution of Apo-ferritin: DFO resulted in the appearance of an orange-red color.
Journal of inorganic biochemistry  •  2004  |  View Paper
Desferrioxamine prevented death caused by Fe+3 , had no significant effect of the toxicity of Zn+2, and increased that caused by Cu+2.
Brain Research  •  2001  |  View Paper
This residual MPP+ production appeared to be iron‐dependent since it was decreased (30 to 50%) by iron chelators, i.e., deferoxamine or phenanthroline, and was enhanced (by approximately 40%) in the presence of ADP‐Fe3+.
Glia  •  1995  |  View Paper
The relatively slow binding of Fe(III) by deferrioxamine also affected lipid peroxidation, an iron-dependent process.
Archives of biochemistry and biophysics  •  1992  |  View Paper
Show More